New CAR-T therapy shows promise for Hard-to-Treat blood cancers

NCT ID NCT03960840

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 20 times

Summary

This study tests a new treatment called rapcabtagene autoleucel (YTB323) for adults with certain blood cancers like chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), and acute lymphoblastic leukemia (ALL). The treatment uses a patient's own immune cells that are modified to attack cancer. The study aims to see if it is safe and effective, either alone or combined with another drug (ibrutinib). About 217 people will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

H Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
Mass Gen Hosp Cancer Center

Boston, Massachusetts, 02114, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Novartis Investigative Site

Melbourne, Victoria, 3000, Australia
Novartis Investigative Site

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site

Vienna, 1090, Austria
Novartis Investigative Site

Marseille, 13273, France
Novartis Investigative Site

Paris, 75475, France
Novartis Investigative Site

Pierre-Bénite, 69495, France
Novartis Investigative Site

Rennes, 35033, France
Novartis Investigative Site

Frankfurt am Main, Hesse, 60590, Germany
Novartis Investigative Site

Leipzig, Saxony, 04103, Germany
Novartis Investigative Site

Essen, 45147, Germany
Novartis Investigative Site

Bergamo, BG, 24127, Italy
Novartis Investigative Site

Milan, MI, 20132, Italy
Novartis Investigative Site

Rozzano, MI, 20089, Italy
Novartis Investigative Site

Sapporo, Hokkaido, 060-8648, Japan
Novartis Investigative Site

Bunkyo Ku, Tokyo, 1138677, Japan
Novartis Investigative Site

Fukuoka, 8128582, Japan
Novartis Investigative Site

Badalona, Barcelona, 08916, Spain
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Barcelona, 08041, Spain
Novartis Investigative Site

Córdoba, 14004, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Salamanca, 37007, Spain
Novartis Investigative Site

Seville, 41013, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37221, United States
St Davids South Austin Medical Ctr

Austin, Texas, 78704, United States
Stanford University Medical Center

Stanford, California, 94305-5826, United States
Uni Of TX MD Anderson Cancer Cntr

Houston, Texas, 77030, United States
Uni of Chi Medi Ctr Hema and Onco

Chicago, Illinois, 60637, United States
University of California LA

Los Angeles, California, 90095, United States
University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
University of Pennsylvania Clinical

Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.

ACUTE LYMPHOBLASTIC LEUKEMIA CHRONIC LYMPHOCYTIC LEUKEMIA DIFFUSE LARGE B CELL LYMPHOMA LARGE B-CELL LYMPHOMA LARGE B-CELL LYMPHOMA SMALL LYMPHOCYTIC LYMPHOMA